Valuation: Lucy Scientific Discovery Inc.

Capitalization 907K 768K 708K 668K 1.25M 84.54M 1.27M 8.31M 3.25M 40.59M 3.4M 3.33M 144M P/E ratio 2022 *
-
P/E ratio 2023 -1.63x
Enterprise value 1.02M 866K 798K 753K 1.4M 95.25M 1.43M 9.36M 3.66M 45.73M 3.83M 3.75M 162M EV / Sales 2022 *
-
EV / Sales 2023 2,682,682,605x
Free-Float
69.61%
Yield 2022 *
-
Yield 2023 -
1 month+100.00%
3 months-33.33%
6 months-33.33%
Current year-33.33%
1 week 0
Extreme 0.0002
0
1 month 0
Extreme 0.0002
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.02
3 years 0
Extreme 0
17
5 years 0
Extreme 0
40
10 years 0
Extreme 0
40
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 75 2021-01-31
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00%0.00%-100.00% 352
-1.89%-5.06%+19.53%+141.52% 810B
-0.60%-1.09%+55.36%+43.92% 575B
-0.88%-1.50%+17.88%+28.98% 369B
-0.22%+0.48%+23.57%+13.94% 324B
-0.31%-3.46%+43.83%+24.73% 311B
-1.72%-4.29%+50.40%+2.25% 291B
-0.61%-3.40%+30.47%+33.96% 289B
-0.78%-0.45%+17.92%+39.29% 188B
-0.48%-1.25%+32.26%+68.40% 173B
Average -0.49%-1.38%+29.12%+29.70% 333.04B
Weighted average by Cap. -0.33%-1.29%+32.42%+57.79%

Financials

2022 2023
Net sales - 0.01 0.01 0.01 0.01 0.01 0.66 0.01 0.06 0.03 0.32 0.03 0.03 1.12
Net income -5.86M -4.96M -4.57M -4.31M -8.05M -546M -8.17M -53.65M -21M -262M -21.97M -21.51M -931M -8.99M -7.61M -7.02M -6.62M -12.35M -838M -12.55M -82.34M -32.23M -402M -33.72M -33.02M -1.43B
Net Debt 4.77M 4.04M 3.72M 3.51M 6.55M 444M 6.65M 43.66M 17.09M 213M 17.88M 17.51M 757M 115K 97.35K 89.77K 84.65K 158K 10.71M 160K 1.05M 412K 5.14M 431K 422K 18.26M
Logo Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
Employees
2
Date Price Change Volume
26-04-13 0.000200 $ 0.00% 559
26-04-10 0.000200 $ 0.00% 625

Quarterly revenue - Rate of surprise